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S100B is an EF-hand calcium-binding protein that exerts both intracellular and extracellular eﬀects on a variety of cellular
processes. The protein is predominantly expressed in the central nervous system by astrocytes, both physiologically and during
the course of neurological disease. In the healthy adult brain and during development, constitutive S100B expression acts as a
trophic factor to drive neurite extension and to referee neuroplasticity. Yet, when induced during central nervous system disease,
the protein can take on maladaptive roles and thereby exacerbate brain pathology. Based on genetic and pharmacological lines of
evidence, we consider such deleterious roles of S100B in two common brain pathologies: ischemic stroke and Alzheimer’s disease
(AD).Inrodentmodelsofischemicbraindamage,S100Bisinducedearlyonduringthesubacutephase,whereitexacerbatesgliosis
and delayed infarct expansion and thereby worsens functional recovery. In mouse models of AD, S100B drives brain inﬂammation
and gliosis that accelerate cerebral amyloidosis. Pharmacological inhibition of S100B synthesis mitigates hallmark pathologies of
both brain diseases, opening the door for translational approaches to treat these devastating neurological disorders.
1.Introduction
Theprincipalcelltypescomprisingthebrainparenchymaare
neurons and glial cells. The term “glia” is customarily used
to refer to neuroglia (comprised of astrocytes, oligodendro-
cytes, and more recently, NG2 oligodendrocyte progenitors),
Schwann cells, and central nervous system- (CNS-) resident
macrophages known as microglia. Occasionally, ependymal
cells (ependymoglia) are also classiﬁed as glia, as they
are diﬀerentiated from radial glia [1] and share astrocytic
properties [2]. In addition to parenchymal cells, cerebral
vascular cells exist and form a physiological barrier in the
CNS known as the blood-brain barrier (BBB). Among these
cellular constituents, astrocytes greatly outnumber neurons
in the brain, making up about 50% of human brain volume
[3]. Despite the time-honored concept that astrocytes are
“silentpartnersoftheworkingbrain”,accumulatingevidence
has shown that astrocytes are active participants in CNS
physiology [4–6], including transport of substances between
blood and neurons [3, 4], cerebral blood ﬂow metabolism
control [7–10], modulation of synaptic transmission [11–
13], synaptogenesis [14–18], and neurogenesis [19–22].
Yet, astrocytes are capable of directly endangering neu-
rons during the course of inﬂammatory CNS disorders [23,
24]. In fact, acute and chronic CNS disorders often have a
component of glial activation, characterized by inﬁltration
of activated microglia and astrocytes into the region of
damaged tissue [21, 25–28]. Reactive astrocytes likely exert
theireﬀectsincollaborationwithactivatedmicroglia.Onthe
one hand, these cells may exacerbate neuroinﬂammation by
producing a myriad of toxic substances, including cytokines,
nitric oxide, prostanoids, and reactive oxygen species; on the
other hand, they are capable of exerting beneﬁcial eﬀects
by producing neurotrophic substances [3–6, 21, 25, 29, 30].
Much recent attention has been focused on this enigmatic
duality so often observed in studies of activated glia within2 Cardiovascular Psychiatry and Neurology
the broader context of neurological and neurodegenerative
diseases.
This paper begins by addressing the double-edged sword
of both beneﬁcial and detrimental actions of astrocytic
S100B in the CNS. Subsequently, we move on to focus
on contributions of reactive astrocytes to glial inﬂamma-
tory responses in two common neurodegenerative diseases:
cerebral ischemia and Alzheimer’s disease (AD). Finally, we
consider the concept of translating S100B inhibition to the
clinic for the treatment of neurodegenerative diseases.
2. Beneﬁcial andDetrimental Actions of
S100Binthe CentralNervousSystem
S100 is a large family (over 20 members) of EF-hand
(helix E-loop-helix F) calcium-binding proteins, and all
but four are clustered on human chromosome 1q21, while
the human gene encoding S100B maps to chromosome
21q22 [31–38]. A total of ten S100 family members are
expressed in the brain, including S100A1, S100A2, S100A4,
S100A5, S100A6, S100A10, S100A11, S100A13, S100B, and
S100Z. In addition, mRNA levels of S100A1/S100B are 5-
fold higher than S100A6/S100A10 and 100-fold higher than
S100A4/S100A13 in the mouse brain. Five of these six family
members (S100A1, S100A6, S100A10, S100A13, and S100B)
areincreasedinanage-dependentmannerinadultmice[39].
S100B is detected in varying abundance in a limited number
of brain cells including astrocytes, maturing oligodendro-
cytes, neuronal progenitor cells, pituicytes, ependymocytes,
and certain neural populations. Although the majority of
astrocytic S100B localizes within the cytoplasm, 5%–7% is
membrane bound [32, 34, 38, 40–42]. S100B has been impli-
cated in Ca2+-dependent regulation of a variety of intracel-
lular functions such as protein phosphorylation, enzymatic
activity, cell proliferation and diﬀerentiation, cytoskeletal
dynamics, transcription, structural organization of mem-
branes, intracellular Ca2+ homeostasis, inﬂammation, and
protection against oxidative damage [31–38, 43–46].
Binding of S100B to receptors on target cells releases
intracellular free Ca2+ from Ca2+ stores via activation of
phospholipaseCanddownstreaminositoltriphosphate[43].
As overexpression of S100B induces downregulation of
p53 protein [47], calcium signaling and S100B may act
in cooperation with this pathway, which is implicated in
growth inhibition and apoptosis [47–49]. Yet, how elevation
of cytosolic Ca2+ transduces S100B binding into trophic and
proliferative eﬀects on brain cells is still elusive.
During brain development, a temporal correlation has
been reported between synaptogenesis and astrocyte diﬀer-
entiation [50]. Numerous ﬁndings support the notion that
astrocytes regulate the formation, maturation, and main-
tenance of synapses [14–17]. Astrocytic S100B expression
increases in the rodent brain during the ﬁrst 3 postnatal
weeks—a critical period for glial proliferation and synap-
togenesis, and it was suggested nearly 40 years ago that the
protein likely referees synaptic development in vivo [51, 52].
In the adult rodent brain, S100B expression persists at
nanomolar concentrations and likely orchestrates neurite
extension [53], enhances survival of neurons and promotes
synapse formation [54] ,a n de x e r t sp r o t e c t i v ea c t i o n sa f t e r
injury [55, 56].
On the other hand, there is accumulating evidence that
S100B may also have detrimental actions in the CNS. Activa-
tion of microglia triggers and promotes astrocytic activation
through release of cytokines such as tumor necrosis factor-
α (TNF-α) and interleukin-1β (IL-1β). These and other
cytokines drive a synergistic relationship between these two
types of glial cells via a vicious positive feedback loop known
as the “cytokine cycle” [24]. While numerous bioactive
substances are part and parcel of this cycle, S100B can be
regarded as a major constituent of this brain-damaging feed-
back loop. In this context, Hu and colleagues demonstrated
that S100B at micromolar concentrations induces neuronal
damage in a neuron and astrocyte coculture experiment by
causing overexpression of inducible nitric oxide synthase
and subsequent release of nitric oxide [57]. Lam and
colleagues showed that S100B stimulates inducible nitric
oxide synthase in rat primary cortical astrocytes through
a signal transduction pathway that involves activation of
the transcription factor nuclear factor-κB( N F - κB), which
is a master regulator of pro-inﬂammatory responses [58].
Hu and Van Eldik showed that S100B upregulates IL-1β
expression in astrocytes [59], and Ponath and coworkers
showed that S100B stimulates release of IL-6 and TNF-α
from astrocytes [60].
Importantly, numerous secreted S100 proteins (S100B,
S100A1,S100A2,S100A4,S100A5,S100A6,S100A7,S100A8/
A9, S100A11, S100A12, and S100P) can act in either an
autocrine or paracrine fashion through a common receptor:
the receptor for advanced glycation endproducts (RAGE), a
multiligand receptor that belongs to the immunoglobulin
family. Moreover, in cell-based assays, all these family
members (except for S100A2 and S100A5) have been
shown to trigger RAGE-dependent signaling [38, 61–65].
The fact that the RAGE promoter has functional NF-κB
binding sites reinforces the likelihood that this signaling
pathway is an important trigger of inﬂammatory patho-
genesis [66]. Moreover, it has been shown that RAGE
and S100/calgranulin signaling propagate, recruit, and acti-
vate cellular pro-inﬂammatory eﬀectors [61]. Accordingly,
nanomolar concentrations of extracellular S100B can trigger
expression of the anti-apoptotic factor Bcl-2 in RAGE-
expressing cells, whereas micromolar S100B concentrations
induce apoptosis via RAGE activation [67]. In primary
microglia, S100B stimulates IL-1β production by activat-
ing extracellular signal-regulated kinase 1/2 (ERK1/2), p38
mitogen-activated protein kinase (p38 MAPK), and c-Jun
NH2 terminal protein kinase (JNK) [68]. There is evidence
thatS100B-mediatedmicroglialpro-inﬂammatoryresponses
are RAGE-dependent, as RAGE ligation by S100B induces
expression of the pro-inﬂammatory enzyme cyclooxygenase-
2 (COX-2) via parallel Ras-Cdc42-Rac1-dependent activa-
tion of JNK and Ras-Rac1-dependent stimulation of NF-κB
transcriptional activity. Further,S100B engagementofRAGE
coordinately stimulates NF-κB and AP-1 transcriptional
activity and synergizes with IL-1β and TNF-α to upregulate
COX-2 expression [65].Cardiovascular Psychiatry and Neurology 3
3.ReactiveAstrocytesand
S100B in Cerebral Ischemia
While there is a wide spectrum of various forms of brain
damage, ischemic stroke (cerebral ischemia) is the most
prevalent type of brain injury that causes death and long-
lasting disability. The pathogenic eﬀects of microcirculatory
dysfunction in cerebral ischemia can be divided into two
categories: impairment of intraluminal cerebral blood ﬂow
andextraluminaleﬀectsresultingfromalterationsintheBBB
[69]. Over the past decade, extensive research eﬀorts have
been directed toward development of neuroprotective drugs
against cerebral ischemia, such as ion channel antagonists,
glutamate receptor antagonists, and free radical scavengers.
Anti-platelet drugs, anti-thrombotic drugs, tissue plasmino-
gen activators, and free radical scavengers have already come
into routine clinical use and clinical trials investigating
additional agents are ongoing.
In the clinical setting, S100B is a well-known biomarker
that positively associates with severity of brain damage and
has been shown to predict prognosis after subarachnoid
hemorrhage [70, 71], ischemic brain injury [72, 73], and
traumatic brain injury [74]. It is important to note that the
above clinical studies are correlative in nature and presume
that rise in cerebral spinal ﬂuid and serum concentrations of
S100B is due to release of intracellular stores of the protein
upon cellular disruption. Thus, the possibility that S100B is
synthesized de novo by reactive astrocytes and exacerbates
infarct evolution was not considered in these reports. In
addition, a surge of attention from both physiological and
therapeutic standpoints has been directed toward the possi-
ble roles of astrocytes in neurometabolic and neurovascular
coupling.
After focal cerebral ischemia, brain damage is accom-
panied by inﬁltration of reactive astrocytes into the peri-
infarct area. Speciﬁcally, astrocytes are copiously activated
along the outer border of the infarct. Reactive astrocytes
are earmarked by increased expression of S100B and glial
ﬁbrillary acidic protein (GFAP), appear around 24 hours
after the onset of ischemia, and undergo hypertrophy and
hyperplasia for a period of weeks thereafter [75–77]. During
the chronic disease phase (>168 hours post-ischemia),
astrocytes extensively wall oﬀ the BBB at the glial limitans
[78]( Figure 1), participate in angiogenesis concurrent with
development of cerebral edema [29, 79], and possibly drive
neurogenesis [19, 22]. On the other hand, when considering
the subacute phase (24–168 hours after ischemia onset) of
this neurological disorder, it has been diﬃcult to assign a
roletoreactiveastrocytes.Thisisowedtothelong-heldbelief
that infarct expansion after focal cerebral ischemia comes to
a complete halt by 12 hours, well before astrocytic activation
manifests [80]. However, “delayed infarct expansion” during
the subacute phase of cerebral ischemia was later discovered
and is now becoming generally accepted. This pathological
event has led to a wider recognition of the possible detri-
mental role of astrocytic activation in the subacute phase of
cerebral infarction as a valid research target [81].
With regard to the concept of delayed infarct expansion,
Garcia and colleagues used the rat permanent focal cerebral
IA
PIA
(a)
(b)
Figure 1:Reactiveastrocytes,earmarkedbyenhancedexpressionof
glialﬁbrillaryacidicprotein,hyperplasia,andgemistocyticchanges,
form a glial barrier in the peri-infarct area of a mouse brain at 7
days post-focal cerebral ischemia. Higher magniﬁcation image (b)
representstheinsetofthelowermagniﬁcationcoronalbrainsection
(a). Abbreviations used: IA: infarct area; PIA: peri-infarct area. Bars
denote 500μm (a) and 50μm( b ) .
ischemia model and noted for the ﬁrst time in 1993 that
there was a signiﬁcant increase in infarct area during the
time interval between 6 and 72 hours after ischemia onset
[76]. In 1996, Du and coworkers followed up by showing
that infarction after mild transient focal cerebral ischemia
could develop in a delayed fashion in the rat [82]. Using
the rat permanent focal cerebral ischemia model, we have
shown that after the rapid expansion phase during the ﬁrst
24 hours post-insult, infarct volume continues to slowly but
steadily increase until it reaches a peak at 168 hours. At this
time-point, there is a signiﬁcant increase in infarct volume
of ∼41% as compared to 24 hours post-insult. Moreover, the
occurrence of delayed infarct expansion is associated with
astrocytic activation as well as increased abundance of S100B
in the peri-infarct area [81]. Clinical research relying on
magnetic resonance imaging of ischemic stroke patients has
disclosed that infarct expansion occurs during two distinct
phases (acute and delayed) [83–85], and the time course and
magnitude of ischemic enlargement are quite comparable
between patients and the rat permanent focal cerebral
ischemia model [81]. The above lines of evidence reinforce
the idea that delayed infarct expansion is a viable therapeutic
target and may even be as important as acute infarct
expansion in terms of disease progression. Moreover, the4 Cardiovascular Psychiatry and Neurology
association among the appearance of numerous peri-infarct
reactiveastrocytes,increasedabundanceofS100Bintheperi-
infarct area, and occurrence of delayed infarct expansion has
emerged as an issue of high clinical importance.
Based on the work discussed above, we undertook a
series of experiments to investigate the putative causal
relationship between S100B and exacerbation of brain
damage. Speciﬁcally, we forced expression of human S100B
or pharmacologically blocked S100B biosynthesis in rodents
subjected to ischemic brain injury. We discuss our relevant
ﬁndings to follow.
3.1. Human S100B Exacerbates Ischemic Brain Damage and
Peri-Infarct Gliosis. We sought to evaluate whether forced
expression of human S100B in astrocytes may exacerbate
brain damage and delayed infarct expansion after permanent
focal cerebral ischemia. As a corollary, we aimed to examine
whether severity of delayed infarct expansion and peri-
infarct gliosis were correlated. To experimentally probe these
questions,weutilizedtransgenicmiceoverexpressinghuman
S100B (Tg huS100B mice; carrying approximately 10 copies
of the human S100B gene under endogenous regulatory
control) on an outbred CD-1 genetic background. These
transgenic mice overexpress S100B in cortical astrocytes by
4-6-fold over endogenous wild-type levels [86]. We perma-
nently induced focal cerebral ischemia by tandem occlusion
of the left common carotid artery and distal segment
of the middle cerebral artery using an electrocoagulation
method under normothermia [87]. Notable results of this
experiment are that Tg huS100B versus control CD-1 mice
showsigniﬁcantexacerbationofinfarctvolume,neurological
deﬁcits, and peri-infarct-reactive gliosis (astrocytosis and
microgliois) during the time interval between 1 and 7 days
after the onset of ischemia, providing evidence for increased
susceptibility of Tg huS100B mice to ischemic brain stress.
Moreover, reactive gliosis as indicated by increased S100,
GFAP, and Iba1 immunoreactivity in the peri-infarct area
continued to increase in Tg huS100B mice through to 7 days
after focal cerebral ischemia, whereas control mice reach a
plateau at 3 days following ischemic insult.
Our interpretation of the above evidence is that pro-
inﬂammatory events associated with S100B-accelerated glial
activation in the peri-infarct area contribute to exacerbation
of brain damage. In further support of this conclusion, we
noted a positive correlation between reactive gliosis along
the infarct border and occurrence of delayed infarct expan-
sion in Tg huS100B mice, but no signiﬁcant relationship
between these variables was detected in control animals.
Together, these results support the notion that enhanced and
prolonged activation of glial cells plays a detrimental role
during the subacute phase (1 to 7 days) of focal cerebral
ischemia in the rodent brain [81, 87, 88]. Moreover, our
results also bolster the hypothesis that astrocyte-derived
S100B is a pivotal mediator of these deleterious eﬀects [88–
90]. In addition, we found that Tg huS100B mice had higher
constitutive levels of S100 as compared with CD-1 mice.
The distinction between constitutive and ischemic brain
injury-enhancedS100isimportant.Thisisbecauseincreased
baseline S100 abundance may predispose to worse acute
infarct expansion within 1 day after ischemic induction,
whereasfurtherinductionofS100expressionlikelypromotes
exacerbation of delayed infarct expansion.
As mentioned above, astrocytes and astrocyte-derived
S100B seem to play dichotomous roles in progression of
various CNS pathologies, although it is still controversial
whether, on average, detrimental eﬀects outweigh neuropro-
tective eﬀects or vice versa. Since S100B can be trophic to
glia[91],thiseﬀectmaymechanisticallyunderliehyperplasia
of peri-infarct reactive glia after focal cerebral ischemia in
Tg huS100B mouse brains. Interestingly, aged rats show
accelerated glial reactivity after cerebral ischemia, which
coincides with impaired functional recovery [92]. Thus,
worsening of neurological deﬁcit in Tg huS100B mice after
focal cerebral ischemia may be caused by inappropriately
accelerated “trophic” glial responses.
The above studies adopted a genetic approach to demon-
strate in vivo evidence that forced expression of human
S100B exacerbates brain damage, neurological deﬁcits, and
peri-infarct reactive gliosis after ischemic stress. However,
whether S100B sits at the epicenter of the damaging cytokine
cycle and delayed infarct expansion needed further veriﬁca-
tion. To deﬁnitively validate this hypothesis, we examined
whether pharmacological blockade of S100B biosynthesis
would produce converse eﬀects on ischemic brain damage.
As detailed below, we found support that pharmacological
strategies aimed at inhibiting S100B abundance would, in
principle, be beneﬁcial to mitigate cerebral ischemia.
3.2. Suppressing S100B Synthesis Mitigates Cerebral Ischemic
Brain Damage. To examine if enhanced synthesis of
S100B by peri-infarct reactive astroglia played a role in
delayed infarct expansion, we undertook a pharmacological
approachusing a novel agent, arundic acid [ONO-2506, (R)-
(–)-2-propyloctanoic acid, ONO Pharmaceutical Co. Ltd.],
which has been shown to suppress astrocytic S100B synthesis
[93]. Yet, arundic acid exerts additional eﬀects both in vitro
and in vivo on other biomolecules, including inhibition
of nerve growth factor-β, inducible nitric oxide synthase,
and COX-2 expression and increasing glutathione synthe-
sis, mRNA expression of glutamate transporters (gluta-
mate transporter subtype 1: GLT-1 and glutamate/aspartate
transporter: GLAST) and GABA receptors (GABAA-R β1,
GABAA-R β2, and GABAA-R β3) in activated astrocytes.
Yet, it is still unclear whether the agent modulates these
other proteins directly or indirectly via its suppressive
eﬀect on S100B [93]. To model ischemic brain injury in
the rat, we permanently occluded the left middle cerebral
artery under normothermia and then divided at a site
proximal to the origin of the lenticulostriate arteries [81].
Intravenous administration of arundic acid (10mg/kg, once
a day), initiated immediately after induction of ischemia,
signiﬁcantly reduced infarct volume at 168 hours (but not
at 72 hours) in this rat focal cerebral ischemia model.
Surprisingly,theagentdidnotinhibitacuteinfarctexpansion
during the initial 24 hours, but almost completely inhibited
delayed infarct expansion.
In a subsequent experiment designed to elucidate a
therapeutic window, rats were allocated to groups thatCardiovascular Psychiatry and Neurology 5
received the ﬁrst administration of drug at 24, 48, or 72
hours after focal cerebral ischemia, and infarct volumes
were compared at 168 hours. Treatment with arundic acid
commenced at 24 or 48 hours after the induction of ischemia
signiﬁcantly decreased infarct volumes at 168 hours by
approximately 43% and 35%, respectively. However, when
treatment was initiated later on at 72 hours, we did not
observe a protective eﬀect. Collectively, these results show
an encouraging liberal therapeutic window, which coincides
with the peak of astrocytic S100B synthesis induction after
focal cerebral ischemia. Numbers of apoptotic cells in the
ischemichemisphereat72hourspost-focalcerebralischemia
were markedly decreased by arundic acid treatment. In
addition, tissue levels of S100B as well as GFAP in the peri-
infarct area were signiﬁcantly decreased by the agent. Thus,
administration of arundic acid led to signiﬁcant attenuation
of astrocytic S100B synthesis, general inhibition of astrocytic
activation, and reduced numbers of apoptotic cells in the
peri-infarct area. Notably, delayed infarct expansion was
almost completely inhibited in this experimental disease
model. In addition, we found signiﬁcant improvement in
neurological scores and spontaneous activities as early as
one day after the ﬁrst drug treatment, and these beneﬁcial
outcomes continued for several days after treatment. These
results support the concept that pharmacological inhibition
of astrocytic S100B limits occurrence of delayed infarct
expansion after focal cerebral ischemia.
As arundic acid does not signiﬁcantly inhibit infarct
expansion in the rat focal cerebral ischemia model when
given beyond the 72-hour time-point, the above results
indicate that the compound acts to improve later brain dys-
function through a mechanism that is temporally unrelated
to inhibition of subacute infarct expansion. In this regard,
it has been reported that transient focal cerebral ischemia
is accompanied by relatively widespread and persistent
functional disturbances in the peri-infarct region [94, 95].
Thus, improvement in neurological deﬁcit observed after
the subacute phase is likely ascribable to the beneﬁcial
actions of arundic acid on functional disturbances in the
ischemic hemisphere as well as on neural plasticity in
both ischemic and non-ischemic hemispheres. That neural
functional derangement and delayed infarct expansion can
be simultaneously mitigated by arundic acid raises the
possibility that both pathologies stem from a common
pathogenic mechanism: astrocytic activation. With regard
to the relationship between these pathologies, it has been
reported that symptoms can regress despite increase in
infarct volume [25]. Results of this experiment extend
the notion that pharmacological modulation of astrocytic
activation via inhibiting S100B biosynthesis can have long-
lastingeﬀectsonfunctionalrecoveryafterinjury,despiteonly
reducing infarct expansion during the initial subacute phase.
The above lines of evidence from (1) a genetic model
of forced human S100B expression and (2) pharmacological
blockade of S100B biosynthesis bolster a causal relationship
between S100B and exacerbation of ischemic brain damage.
After cerebral ischemia, astrocytes change in shape and
function within a relatively short time-frame, and likely
exert their eﬀects at multiple levels and at diﬀerent phases
of infarct evolution. During the subacute phase of focal
cerebral ischemia, reactive astrocytes seem to promote
delayed infarct expansion by enhancing the viscous cytokine
cycle in collaboration with activated microglia. The work
detailed above reinforces the idea that astrocytic synthesis of
S100B plays a central role in the pathobiology of this disease,
and prompts a mechanistic model wherein activated astro-
cytes, activated microglia, and S100B participate in brain
damage and delayed infarct expansion after focal cerebral
ischemia (Figure 2). A similar pathogenic mechanism seems
to exist during the course of chronic neurodegeneration
after focal cerebral ischemia in remote areas such as the
thalamus, striatum, and substantia nigra. Since augmented
astrocytic S100B synthesis accompanies a diverse number
of brain pathologies, we moved on to consider the role(s)
of this enigmatic molecule in neurodegenerative disease. In
particular, we focused on of the relationship between S100B
and AD pathology, as detailed to follow.
4. Alzheimer’s Disease,
Neuroinﬂammation, and S100B
AD is the most common progressive dementia of aging
and is characterized by memory loss and gradual decline
in cognition. AD neuropathological hallmarks include brain
deposition of amyloid-β (Aβ) peptide as senile plaques,
accumulation of abnormal tau protein ﬁlaments as intracel-
lularneuroﬁbrillarytangles,extensiveneuronaldegeneration
and loss, profound synaptic loss, and β-amyloid plaque-
associated astrocytosis and microgliosis [96–98]. Moreover,
augmented expression of S100B has been reported in the
brains of patients with Down’s syndrome and in AD
[99]. In AD, it has been shown that S100B abundance is
elevated in activated astrocytes colocalized with β-amyloid
plaques, where progressive expression of IL-1α by activated
microglia has also been noted [100]. Importantly, it has been
reported that astroglial overexpression of S100B actually
precedes appearance of neuritic β-amyloid plaques in the
PDAPP mouse model of AD [101], suggesting that S100B
overabundance may drive cerebral β-amyloidosis as opposed
to existing as an epiphenomenon.
BrainAβ deposition“normally”occursduringthecourse
of senile changes [102], and it is probably a combination of
increasedaccumulation/reducedclearanceofthepeptideand
impaired ability to cope with toxic downstream eﬀects of Aβ
that drive AD. Aβ is produced from sequential endoprote-
olytic cleavage of the type 1 transmembrane glycoprotein,
β-amyloid precursor protein (APP), by β-a n dγ-secretases
[103–106]. Recently, it has been hypothesized that newly
produced Aβ enters a dynamic equilibrium between soluble
and deposited forms in the brain, with continual transport
of soluble Aβ out of the brain and into the circulation [107].
In fact, cerebral amyloidosis in AD patient brains might be
licensed by an imbalance in this dynamic equilibrium.
Rooted in the “amyloid cascade hypothesis” of AD,
which purports that accumulation of cerebral Aβ sets
into motion a series of toxic downstream events [108,
109], extensive research eﬀorts have been directed toward6 Cardiovascular Psychiatry and Neurology
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Figure 2: A model for the roles of activated astrocytes, activated microglia, and S100B in delayed infarct expansion after focal cerebral
ischemia. The glial cytokine cycle is represented by dotted lines. Abbreviations used: COX-2: cyclooxygenase-2; [Glu]e:e x t r a c e l l u l a r
glutamate; GLAST: glutamate/aspartate transporter; GLT-1: glutamate transporter subtype 1; GSH: glutathione; IL-1β: interleukin-1β;I L - 6 :
interleukin-6; iNOS: inducible nitric oxide synthase; NF-κB: nuclear factor-κB; NO: nitric oxide; TNF-α: tumor necrosis factor-α;R A G E :
receptor for advanced glycation endproducts; ROS: reactive oxygen species.
development of anti-amyloid therapies aimed at reducing
cerebral Aβ production (e.g., β-o rγ-secretase inhibitors)
[110–113] or enhancing Aβ clearance by targeting brain
immune/inﬂammatory mechanisms [27, 28, 114–123].
Unfortunately, however, agents that demonstrated beneﬁt
in rodent models of AD have not yet lived up to their
promise in the clinic, where cholinesterase inhibitors (e.g.,
donepezil, rivastigmine, tacrine, and galantamine) and N-
methyl D-aspartate antagonist (e.g., memantine) continue
to be prescribed. It should be noted, however, that these
currently indicated drugs produce only modest symptomatic
beneﬁt, especially when administered in the advanced stage
of the disease. Thus, research into new drugs based on
alternative therapeutic targets has continued at a feverish
pace.
Over the past decade, we and others have proposed
that inﬂammatory and immune response pathways are
chronically activated in AD patient brains at low levels, and
likely play a role in disease progression. “Inﬂammation”
is canonically deﬁned as edema and tissue inﬁltration of
neutrophils, lymphocytes, plasma cells, and macrophages,
buttheseclassicalpathologicalﬁndingsarenotpresentinthe
post-mortemADbrain.Yet,accumulatingevidenceindicates
that a variety of factors known to be major participants
in inﬂammatory and immune responses are the norm in
AD. Chronic activation of glial cells in and around β-
amyloid plaques may be pathoetiologic in AD via produc-
tion of numerous neurotoxic acute-phase reactants, pro-
inﬂammatory cytokines, and immunostimulatory molecules
[24, 28, 124, 125]. However, despite low-level, chronic
activation of innate immunity and inﬂammatory responses
in the AD brain, glial cells ultimately fail to clear cerebral β-
amyloid plaques.
Astrocytes and microglia are the main innate immune
responseeﬀectorsintheCNS.Imbalancesbetweenprotective
and destructive functions of these cells might impact neu-
rotoxicity and/or synaptotoxicity in the context of neurode-
generative disease. In the AD brain, reactive astrocytes and
microglia co-exist in both temporal and spatial proximity
withβ-amyloid plaques (Figure 3), and it is thought that dif-
fuse β-amyloid deposits attract and activate IL-1β-secreting
microglia, which in turn activate astrocytes and promote
astrocyte-derived S100B synthesis. This self-propagating
neuroinﬂammatory loop promotes further release of pro-
inﬂammatory cytokines and acute-phase reactants by both
activated microglia and astrocytes, leading to production of
oxyradicals and nitric oxide, which are toxic at supraphys-
iologic levels. Aside from further enhancing inﬂammatory
responses, these pro-inﬂammatory substances likely induce
bystander neuronal injury in the AD brain [24, 124].
Given the conspicuous role of brain inﬂammation and
activated astrocytes in AD pathobiology, we undertookCardiovascular Psychiatry and Neurology 7
(a)
(b)
Figure 3: Numerous β-amyloid plaque-associated reactive astro-
cytes (positive for glial ﬁbrillary acidic protein) are shown in a
coronal brain section from a Tg2576 Alzheimer’s disease model
mouse at 19 months of age. Higher magniﬁcation image (b)
representstheinsetofthelowermagniﬁcationcoronalbrainsection
(a). Arrows show β-amyloid plaques that are surrounded by glial
ﬁbrillary acidic protein-positive processes in the plaque periphery.
Bars denote 500μm (a) and 50μm( b ) .
genetic and pharmacological approaches to target S100B in
ordertoexploreaputativecausalrelationshipbetweenS100B
and progression of AD-like pathology. Our relevant ﬁndings
are reviewed and discussed in the following sections.
4.1. Overexpression of Human S100B Exacerbates Alzheimer’s
Disease-Like Pathology. Over the past decade, numerous
transgenic mouse models have been constructed using
mutations in human APP and/or presenilin-1 that cause
autosomal dominant early-onset AD [126]. To date, at least
ﬁvelinesthatbearmutanthumanAPPgenes,thatis,Tg2576,
PDAPP, APP23, TgCRND8, and J20, have been reported
and are widely used. These transgenic mouse lines diﬀer
in terms of genetic characteristics (e.g., diﬀerent mutations,
promoters, and/or genetic backgrounds), yielding diﬀerent
transgene expression levels and varying severity of AD-
like pathology. Given its wide usage as a mouse model
of AD-like pathology, we adopted Tg2576 mice originally
developed by Karen Hsiao and colleagues in the mid-90s
[127]. This mouse line overproduces human Aβ1-40 and
Aβ1-42 and develops progressive β-amyloid deposits and
learning and memory impairment beginning at 9-10 months
of age [127–129]. To examine a possible role of S100B in the
progression of AD-like pathology, we undertook a genetic
approach to overproduce S100B by crossing transgenic
mice expressing human S100B (TghuS100B mice) [86]w i t h
Tg2576 animals [127] to yield four genotypes of littermates:
Tg2576, Tg2576-huS100B, TghuS100B, and wild-type. We
then examined AD-like pathology in aged animals, including
brainparenchymalandcerebralvascular β-amyloiddeposits,
Aβ levels, β-amyloid deposit-associated gliosis (astrocytosis
and microgliosis), and pro-inﬂammatory cytokines.
We initially noted that the huS100B transgene exacer-
bated age-dependent cerebral amyloidosis, including brain
parenchymal and cerebral vascular β-amyloid deposits
in bitransgenic mice. We also undertook a biochemical
approach to measure diﬀerent forms of Aβ peptides. Con-
sistent with histological results, we noted elevated soluble
and insoluble Aβ1-40 and Aβ1-42 abundance. In brain areas
examined early on during the course of Aβ deposition
(at 9 months of age), we observed that Tg2576 mice had
mainly dot-like β-amyloid deposits (<5μmi nm a x i m u m
diameter); by contrast, Tg2576-huS100B mice had large-
sized β-amyloid plaques (>50μm in maximum diameter)
that were already present at this early age. In addition, as we
did not observe β-amyloid deposits in Tg2576 or Tg2576-
huS100B mice at an even earlier age (7 months), the main
diﬀerence between bigenic and singly-transgenic Tg2576
mice is higher plaque burden in the former, but not that
amyloid deposition is initiated earlier in Tg2576-huS100B
mice. Our ﬁndings can thus be interpreted as accelerated
AD-like pathology by up to 4 months of age in TghuS100B-
Tg2576 versus Tg2576 mice.
We also noted augmented astrocytosis and microgliosis,
elevated levels of endogenous mouse S100 expression, and
increased levels of pro-inﬂammatory cytokines (TNF-α and
IL-1β) as early as 7–9 months of age in bigenic animals—
prior to the onset of frank cerebral amyloid deposits in
Tg2576 mice. Others have reported that gliosis is consequent
upon progressive cerebral amyloid burden in AD model
mice, given that glial activation is proportional to β-amyloid
plaque load [130–132]. However, our ﬁnding that gliosis
precedes increased β-amyloid plaque deposition in Tg2576-
huS100B mice instead suggests that S100B-induced glial
inﬂammatory responses drive accelerated β-amyloid load in
these animals. This conclusion is strengthened by our ﬁnd-
ings that Tg2576-huS100B mice have signiﬁcantly enhanced
astrocytosis and microgliosis as compared to Tg2576 ani-
mals, both during initiation of cerebral amyloidosis (at 9
months of age) and at an age prior to β-amyloid deposition
(at 7 months of age). However, it should be noted that we
also measuredpro-inﬂammatory cytokine mRNAs including
TNF-α,I L - 1 β, IL-6, and mouse S100B at 7 months of age,
andwerenotabletodetectanyconsistentdiﬀerencesinthese
cytokinesbetweenthefourgroupsoflittermates.Thus,while
the huS100B and Tg2576 transgenes synergize on increasing
glial surface activation markers prior to formation of β-
amyloid plaques (i.e., at 7 months of age), these two trans-
genes do not seem to cooperatively aﬀect expression of pro-
inﬂammatory cytokines until 9 months of age in this model.
The role of inﬂammatory responses and glial activation
in the AD pathological process is multifarious, and studies8 Cardiovascular Psychiatry and Neurology
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Figure 4: Diagrammatic representation of brain amyloid-β (Aβ) production/clearance, the harmful actions of S100B on Aβ production,
and resultant eﬀects on brain and plasma Aβ levels. In the amyloidogenic pathway, Aβ is primarily produced in neurons from
sequential endoproteolytic cleavage of the type 1 transmembrane glycoprotein, β-amyloid precursor protein (APP), by β-a n dγ-secretases.
Subsequently, soluble Aβ is secreted into the extracellular space, and then enters into a dynamic equilibrium between soluble and deposited
(insoluble, β-amyloid plaque) forms. Continual transport of soluble Aβ occurs into and from the plasma. S100B enhancement of β-secretase
activity promotes Aβ production, resulting in higher soluble and deposited Aβ in the brain. In addition, S100B promotes a damaging glial
cytokine cycle through activation of astrocytes and microglia, resulting in enhancement of the amyloidogenic pathway.
have shown both beneﬁcial and harmful eﬀects of glial
activationonAD-likepathologyinmousemodelsdepending
on the stimulus [90, 114–117, 122, 132]. These results
have led to the conclusion that there are various forms
of gliosis in the context of AD, and not all forms of glial
activation are damaging—some are likely even therapeu-
tically advantageous [26, 123, 133]. The lines of evidence
presented above suggest that brain pro-inﬂammatory events
associated with S100B-dependent glial activation in close
proximity to β-amyloid plaques lead to exacerbation of
AD-like pathology, supporting the notion that chronic and
prolonged activation of glia is detrimental in the context of
neurodegenerative disease [81, 87, 134]. Such ﬁndings lend
further support to the hypothesis that the astrocyte-derived
protein, S100B, exacerbates the pro-inﬂammatory cytokine
cycle, AD-like pathology, and associated brain injury [88–
90]. A model depicting brain Aβ production/clearance, the
harmful actions of S100B on Aβ production, and resultant
eﬀects on brain and plasma Aβ levels is shown in Figure 4.
Astrocyte-derivedS100Bpromotesneuriteextensionand
contributes to synaptogenesis and synapse remodeling in
the developing and in the mature brain under physiological
conditions [31, 32, 34, 38]. However, in the context of
brain pathology such as AD, S100B may confer maladaptive
neuritic changes in β-amyloid plaques. Supporting this
notion, it has been reported that astrocytic overexpression of
S100B drives dystrophic neurite outgrowth, culminating in
theformationofneuritic plaquesinDown’ssyndrome[135],
and that S100B induction precedes appearance of neuritic
β-amyloid plaques in the PSAPP AD mouse model [101].
Thus, S100B may drive conversion of diﬀuse, nonﬁbrillar
β-amyloid deposits to neuritic β-amyloid plaques [30]. It
is noteworthy that, while β-amyloid plaque morphometric
analysisdisclosedsigniﬁcantincreasesinsmall,medium,and
largeplaquesizesubsetsinTg2576-huS100Bmice,weconsis-
tently noted the greatest exacerbation in medium- and large-
sized plaques. Further, the huS100B transgene produced a
number of “gigantic” β-amyloid plaques (>150μm) in aged
bigenicmice.Thesedatacanbeinterpretedasconsistentwith
a role for S100B in the maturation of β-amyloid deposits.
In addition to aﬀecting cerebral parenchymal Aβ burden,
the huS100B transgene also promotes cerebral vascular β-
amyloid deposits. While Aβ synthesis has classically been
regarded to predominantly take place at neuronal synapses,
it has recently been reported that reactive astrocytes sur-
rounding β-amyloid plaques express β-secretase in AD
patients and in Tg2576 mice [136, 137]. Thus, the huS100B
transgene may directly impact astrocytic amyloidogenic APP
metabolism. This would explain both the exacerbation of
parenchymal and cerebrovascular Aβ deposits in bigenicCardiovascular Psychiatry and Neurology 9
mice. But, does S100B accelerate cerebral amyloidosis by
directly promoting amyloidogenic metabolism of APP? To
evaluate this possibility, we examined amyloidogenic β-
carboxyl terminal fragment (β-CTF; also known as C99)
and amino-terminal APP cleavage products (soluble APPβ)
and noted increases in both species in Tg2576-huS100B
versus Tg2576 mice. We also found increased levels of β-
site APP cleaving enzyme 1 (BACE1; commonly known
as β-secretase), and enhanced enzymatic activity in brain
homogenates from Tg2576-huS100B mice. Thus, in addition
to its ability to promote brain inﬂammatory responses, our
data show that S100B has a previously unappreciated role in
directly promoting amyloidogenic APP processing.
The results discussed above using an in vivo genetic
approach can be interpreted as deﬁnitive evidence that
forced expression of human S100B exacerbates AD-
like pathology, including brain parenchymal and cere-
bral vascular β-amyloid deposits, Aβ levels, β-amyloid
deposit-associated astrocytosis and microgliosis, and pro-
inﬂammatory cytokines [138]. These data suggest that
inhibition of S100B represents a novel therapeutic target for
AD. To further explore this tantalizing possibility, we took
a pharmacological approach to blocking S100B biosynthesis,
as detailed below.
4.2.ArundicAcidAmelioratesCerebralAmyloidosisandGliosis
in Alzheimer Transgenic Mice. We have previously shown
that arundic acid negatively regulates S100B synthesis by
suppressing mRNA expression in activated astrocytes [93].
In addition, arundic acid exerts further eﬀects both in
vitro and in vivo on other biomolecules as described above.
To examine whether inhibiting reactive astrocyte-derived
S100B might impact progression of AD-like pathology in the
Tg2576 AD mouse model [127], we orally administered the
S100B biosynthesis blocker, arundic acid, to Tg2576 mice
for 6 months, commencing at 12 months of age (when
β-amyloid plaques are initially present in this AD mouse
model). Strikingly, arundic acid signiﬁcantly suppressed
cerebral amyloidosis in treated Tg2576 mice. Importantly,
β-amyloid deposits were signiﬁcantly decreased in arundic
acid-treated Tg2576 mice, irrespective of size. Concurrent
reductions in brain levels of both soluble and insoluble
Aβ species corroborated our histopathological observations.
Notably, β-amyloid plaque-associated reactive astrocytosis
and microgliosis were also signiﬁcantly inhibited, suggesting
that arundic acid treatment arrested the feed-forward pro-
inﬂammatory cytokine cycle that would be expected to
enable astrocytic activation of microglia.
In terms of a direct mechanism for the beneﬁcial
eﬀects of arundic acid on reducing AD-like pathology, a
number of possibilities deserve consideration. Firstly, the
drug might alter APP expression in Tg2576 mice, either by
aﬀecting endogenous murine APP levels or by modulating
the hamster prion promoter-driven mutant human APP
transgene [127]. Yet, APP expression in brain homogenates
was comparable between arundic acid-treated and vehicle-
treated Tg2576 mice, making this explanation seem unlikely.
Secondly, as long-term administration of indomethacin,
a key inhibitor of the inﬂammatory mediator NF-κB,
signiﬁcantly reduces cerebral amyloidosis in Tg2576 mice
[139], and NF-κB is downstream of S100B [58], it is
possible that arundic acid-induced inhibition of NF-κB
activity may mitigate amyloidosis in Tg2576 mice. In fact,
we previously observed that lipopolysaccharide-induced
activation of NF-κB in cultured astrocytes was signiﬁcantly
attenuated by arundic acid [93]. Thus, it seems likely that
NF-κB inhibition is at least partly responsible for arundic
acid-induced reduction of Aβ pathology in this scenario.
Thirdly, biochemical evidence of decreased brain levels of
soluble and insoluble Aβ—against a backdrop of unaltered
APP production—suggests inhibition of amyloidogenic APP
metabolism in arundic acid-treated Tg2576 mice. Whether
this eﬀect occurs via direct inhibition of β-secretase, or via
an indirect mechanism, remains to be elucidated. Because,
as mentioned above, astrocytes express β-secretase and have
been directly implicated in amyloidogenic APP metabolism
inthecontextofAD[136,137],adirectmechanismofaction
remains possible.
Lastly, in addition to the pro-inﬂammatory eﬀects of
astrocytic S100B, its eﬀects on neural reparative processes
might be related to β-amyloid plaque development. It has
been proposed that synaptic dysfunction occurs in both the
prodromal and the clinical phases of AD [98], and excessive
neuroplastic burden has been postulated to be a prime
mover in the disease process [140]. It has been reported that
astrocytic ﬁlopodia in tripartite synapses sense alterations in
synaptic transmission, leading to their activation [141]. Acti-
vatedastrocytescontributetobothreparativeanddestructive
actions,whichareconsideredtobeatleastpartiallymediated
by altered levels of S100B [142]. Thus, pharmacological
suppression of astrocytic S100B biosynthesis by arundic acid
may have dual roles in delaying disease progression: in
brain regions with relatively low levels of S100B, arundic
acid might inhibit neurite extension in response to cerebral
amyloidosis, and thereby decrease neuroplastic burden. By
contrast, in brain regions where S100B is highly expressed,
the agent may suppress the pro-inﬂammatory autotoxic loop
[24, 30] and thereby reduce β-amyloid plaque maturation.
5. Concluding Remarks
In this paper, we have considered beneﬁcial physiological
functions and detrimental roles of the astrocyte-derived
protein S100B in cerebral ischemia and in AD. Importantly,
we propose that both of these neurological diseases share
a common pathogenic mechanism—maladaptive astrocytic
activation—where S100B acts as a perpetrator of neu-
roinﬂammation and neurotoxicity. Using both genetic and
pharmacological approaches, we have produced evidence
supporting the idea that enhanced and prolonged activation
of astrocytes plays a detrimental role in the pathogenesis of
cerebral ischemia and AD, and that astroctye-derived S100B
is at the epicenter of these damaging cellular responses.
In agreement with these lines of evidence, another group
has demonstrated that S100B transgenic and knockout mice
show worsening and attenuation, respectively, of ischemic
brain damage [143]. In terms of AD, there is evidence
that S100B transgenic mice show enhanced susceptibility to10 Cardiovascular Psychiatry and Neurology
neuroinﬂammation and neuronal dysfunction induced by
intracerebroventricular infusion of human β-amlyoid [144].
Theseandotherstudiesunequivocallysuggestthatinhibiting
astrocytic activation by pharmacological blockade of S100B
biosynthesis may be a valuable therapeutic strategy to com-
bat ischemic stroke and to delay onset and/or progression of
AD. As with any pharmacological approach, it is important
to note that there are advantages and disadvantages to
modulating astrocytic activation via targeting S100B. Since
available data are limited using genetic approach(es) to
elucidate the possible role(s) of S100B in CNS health and
disease, further studies using S100B and RAGE knockout
mice, either singly or doubly-deﬁcient for these genes, are
warranted. The availability of selective S100B biosynthesis
inhibitors such as arundic acid is expected to further trans-
lational research for neurological and neurodegenerative
diseases, and perhaps other disorders, such as inﬂammatory
bowl disease, which are S100B overexpresssion-related. Such
future studies will go on to address the tantalizing possibility
of next-generation therapeutics for ischemic stroke and AD
aimed at the pleiotropic S100B pathway.
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